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The final strategy recommended in American Patients First: The Trump Administration 
Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs is lowering out-of-pocket costs 
for consumers. Key elements highlighted for immediate action include prohibiting gag clauses 
that prevent pharmacists from telling patients when not using insurance would be less expensive, 
and increasing drug price transparency for the consumer. 
There has already been significant movement at both the state and federal level to address the 
issue of gag clauses. Legislation is focused on prohibiting pharmacy benefit managers (PBMs) 
and health plans from preventing pharmacists from disclosing a drug may cost less if the patient 
does not use insurance. For example, a customer using insurance to fill a prescription for 
cholesterol lowering medication may have a $20 copay, while a customer paying cash would 
only pay $10. A pharmacist may be penalized by the PBM (up to and including exclusion from 
their network) if she discloses this discrepancy. According to the National Conference of State 
Legislatures, of the 41 states that were considering legislation to prohibit gag clauses, 28 have 
enacted laws as of December 2018, with over half enacted since March. Of note, Massachusetts 
is one of seven states listed with no specific activity for anti-gag clause legislation.1 
At the federal level, two bipartisan bills that prohibit gag-clauses for Medicare Advantage and 
Part D plans (Know the Lowest Price Act) and for group health plans or health insurance issuers 
(Patient Right to Know Drug Prices Act) were signed into law on October 10, 2018.2,3,4 
While prohibiting gag clauses will allow the customer to be better informed about lower cost 
options, it may adversely impact their overall health care expenses. If the customer does not use 
his insurance for copays, his payment is not put towards his deductible. In addition, the 
difference in the copay and cash amount usually goes back to the PBM as profit. A reduction in 
this profit may lead to PBMs increasing premiums to make up for this loss. 
Another focus for Health and Human Services to lower out-of-pocket cost has been over-the-
counter (OTC) drugs. The Food and Drug Administration (FDA) is looking for ways to improve 
access to OTC medications which may offer lower cost options to treat or manage conditions. In 
order to accomplish this, the FDA has put forth solutions, such as improved technology and new 
approaches to conveying product information to assist patients in safely and accurately self-
medicating. However, the standards to demonstrate the appropriateness of a medication for 
consumer use without the guidance of a health professional will remain high. Draft guidance has 
been issued and proposed rulemaking will provide additional information in the future.5 
Typically, there is more competition for OTC medications as stores will have their own generic 
version in addition to the brand name product. The increase in drugs available as OTC has the 
potential to have a high impact on the agent’s price. However, even with the novel approaches 
the FDA has suggested, the impacts on patient safety will ultimately limit the drugs for which an 
OTC option would be appropriate. 
 
1http://www.ncsl.org/research/health/pbm-state-legislation.aspx 
2https://www.congress.gov/bill/115th-congress/senate-bill/2553/actions 
3https://www.congress.gov/bill/115th-congress/senate-bill/2554/actions 
4https://www.pharmacytimes.com/conferences/ncpa-2018/legislation-signed-into-law-
prohibiting-gag-clauses-for-pharmacies 
5https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613692.htm 
